Key result
Low beta-blocker doses were associated with greater reductions in PINP and PIIINP with spironolactone therapy compared to high beta-blocker doses in heart failure.
Why the study?
Does beta-blocker dose influence cardiac collagen turnover and the effects of spironolactone in patients with heart failure?
Observational (n=88)
Yes
Does beta-blocker dose influence cardiac collagen turnover and the effects of spironolactone in patients with heart failure?
Spironolactone may provide greater benefit in reducing cardiac fibrosis markers in heart failure patients who cannot tolerate upward titration of beta-blocker dosages.
Answers are grounded in this paper and cite their sources.
Suggests beta-blocker dose may modulate spironolactone antifibrotic effects in HF; hypothesis-generating and needs randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cavallari et al. (2007) conducted an observational in heart failure (n=88). Low-dose beta-blockers (< 50% of recommended target dose) and spironolactone vs. High-dose beta-blockers (≥ 50% of recommended target dose) and spironolactone was evaluated on Change in PINP concentration with spironolactone therapy (p=0.02). Low beta-blocker doses were associated with greater reductions in PINP and PIIINP with spironolactone therapy compared to high beta-blocker doses in heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: